2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC was highlighted at the 2024 AACR Annual Meeting.
Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was highlighted at the American Association for Cancer Research 2024 Annual Meeting in San Diego as scientists, clinicians, and other health care professionals and stakeholders from all over the world gathered to share the latest advances in cancer science and medicine.
“Finding cancer cures requires diligence and collaboration among the greatest minds in cancer research,” noted Lucio N. Gordan, MD, FCS President & Managing Physician. “Through our extensive and growing clinical trials research program, FCS is proud to be part of global efforts that are saving lives and enhancing the quality of life for patients and their families.”
FCS provides ongoing access to more than 160 clinical trials within 32 FCS clinics and three Drug Development Units (early-phase) across Florida, in Sarasota, Lake Mary, and Lake Nona. In recent years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with FCS participation, prior to approval.
FCS physician investigators presented findings during oral and poster sessions at the ACCR 2024 Annual Meeting.
FCS abstracts at AACR 2024 Annual Meeting: 068, 075, 132, 141, 156, 163, 291, 6552, 7172, 099, 077, 2565
FCS Director of Drug Development Manish Patel, MD, co-author of nine abstracts:
FCS Associate Director of Drug Development Judy Wang, MD, first author:
FCS Scientific Director of Research and Associate Professor of Medicine, Wake Forest University School of Medicine Lowell Hart, MD, FACP, first author:
Co-authors include FCS Trial Match Specialist and Medical Oncologist and Hematologist (retired) James Reeves Jr., MD, FCS Nurse Specialist Stacey Garofalo RN and members of the FCS Real-World Evidence Team, IT Director Data Science Derek Hall and Informatics Data Scientist Parth Kothiya.
FCS Director of Drug Development, Lake Nona DDU, Cesar Augusto Perez, MD, co-author:
“Our clinical trials research contributes daily to the discovery of ground-breaking new drugs and therapies that are accelerating our understanding of cancer and transforming the standard of care,“ said FCS Director of Late-Phase Clinical Research Bradley Monk, MD.
Dr Monk is co-author of a study conducted at HonorHealth University of Arizona College of Medicine and Creighton University School of Medicine prior to being named to his leadership position at FCS earlier this year, “Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study.”
Abstracts were published in the AACR journal, Cancer Research, following the annual meeting. The American Association for Cancer Research (AACR), the first and largest cancer research organization dedicated to accelerating the conquest of cancer, represents 58,000 members residing in 141 countries.